That CagriSema is approved, or approvable, anywhere as of mid-2026 it is investigational, with its benefitrisk profile still under regulatory review
GIP signalling appears to modulate how nutrients are handled metabolically and may soften the nausea that pure GLP-1 agonism can provoke
The structural consequences of rapid weight loss - including bone density reduction and collagen depletion - develop quietly over months and frequently go undetected until a DXA scan or a significant injury prompts a closer look
The medication is indicated for obese and overweight patients with at least one weight-related disease, such as hypertension (high blood pressure), heart disease, dyslipidemia, and high blood cholesterol levels
Coadministration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan